JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

UNH

251.06

+4.25%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

UNH

251.06

+4.25%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

UNH

251.06

+4.25%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

UNH

251.06

+4.25%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

UNH

251.06

+4.25%↑

Search

AstraZeneca PLC ADR

Затворен

74.43 -0.13

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

74.25

Максимум

74.88

Ключови измерители

By Trading Economics

Приходи

1.7B

3.4B

Продажби

-1.3B

14B

P/E

Средно за сектора

28.847

40.048

Дивидентна доходност

2.16

Марж на печалбата

25.037

Служители

94,300

EBITDA

610M

5B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+24.68% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.16%

2.45%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

9.4B

226B

Предишно отваряне

74.56

Предишно затваряне

74.43

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

AstraZeneca PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.07.2025 г., 08:08 ч. UTC

Печалби

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29.07.2025 г., 06:46 ч. UTC

Печалби

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

1.08.2025 г., 11:10 ч. UTC

Горещи акции

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29.07.2025 г., 11:02 ч. UTC

Печалби

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29.07.2025 г., 11:02 ч. UTC

Печалби

AstraZeneca 2Q EPS $1.58 >AZN.LN

29.07.2025 г., 11:01 ч. UTC

Печалби

AstraZeneca 2Q Rev $14.5B >AZN.LN

29.07.2025 г., 11:00 ч. UTC

Печалби

AstraZeneca Results: H1 and Q2 2025

29.07.2025 г., 08:00 ч. UTC

Пазарно говорене
Печалби

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29.07.2025 г., 07:53 ч. UTC

Пазарно говорене
Печалби

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29.07.2025 г., 07:26 ч. UTC

Пазарно говорене
Печалби

AstraZeneca Shares Look Undervalued -- Market Talk

29.07.2025 г., 06:03 ч. UTC

Печалби

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29.07.2025 г., 06:03 ч. UTC

Печалби

AstraZeneca 2Q Total Revenue $14.46B

29.07.2025 г., 06:03 ч. UTC

Печалби

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29.07.2025 г., 06:03 ч. UTC

Печалби

AstraZeneca 2Q Core EPS $2.17

29.07.2025 г., 06:02 ч. UTC

Печалби

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29.07.2025 г., 06:02 ч. UTC

Печалби

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29.07.2025 г., 06:02 ч. UTC

Печалби

AstraZeneca Backs 2025 View

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q Rev $14.46B

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q Adj EPS $2.17

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q Pretax Pft $3.13B

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q Net Pft $2.45B

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q Oper Pft $3.51B

29.07.2025 г., 06:00 ч. UTC

Печалби

AstraZeneca PLC 2Q EPS $1.57

28.07.2025 г., 10:51 ч. UTC

Пазарно говорене

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22.07.2025 г., 10:19 ч. UTC

Пазарно говорене

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22.07.2025 г., 09:34 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9.07.2025 г., 10:59 ч. UTC

Пазарно говорене

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9.07.2025 г., 09:17 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New -2-

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

AstraZeneca PLC ADR Прогноза

Ценова цел

By TipRanks

24.68% нагоре

12-месечна прогноза

Среден 93 USD  24.68%

Висок 97 USD

Нисък 85 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за AstraZeneca PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 69.55Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.